ESG
Merck leads Asia-Pacific with sustainable packaging shift
ESG: In a first of its kind initiative for Merck’s Asia-Pacific region, the company has reinforced its commitment to environmental sustainability by directly advancing its SMASH Packaging strategy.
As of September 1, Merck has shifted from traditional expanded polystyrene (EPS) insulation to wool-pack insulation for cold-chain shipments within its Life Science business in Australia.
This transition represents a pivotal change in the company’s packaging approach, replacing 3.6 tons of non-recyclable EPS annually.
“By moving to wool- and fibreboard-based insulation for cold-chain shipments, we offer our customers sustainable packaging solutions without sacrificing our customary one-day transit time,” said Rebecca Lee, Managing Director at Merck Life Science.
“This transition reflects Merck’s dedication to reducing our environmental footprint and promoting a more sustainable value chain.”
The innovative wool-based packaging solution, validated for one-day pharmaceutical shipments under Australia’s intense summer conditions, is produced by Planet Protector Packaging. This new insulation method not only eliminates EPS materials from shipments requiring temperature regulation between 2°C and 8°C but also minimises waste by printing packing labels directly onto the fibreboard boxes, reducing the need for separate labels.
This initiative marks an important step towards systematically improving the sustainability of both new and existing packaging, aligning with Merck’s broader environmental goals.
Merck has defined ambitious goals to be achieved by 2030 and 2040 on its global sustainability strategy, which have been approved by the Science Based Targets initiative in May 2022.
These goals include achieving human progress for over one billion people through sustainable science and technology by 2030, fully integrating sustainability into all value chains by 2030, and achieving climate neutrality and reducing resource consumption by 2040.
In reimagining healthcare, Health Industry HubTM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News & Trends - Pharmaceuticals
March PBAC agenda unveiled amid tensions over ‘unprecedented’ volume of submissions
The Department of Health has released the agenda for the March 2025 Pharmaceutical Benefits Advisory Committee (PBAC) meeting, unveiling plans […]
MoreNews & Trends - MedTech & Diagnostics
J&J MedTech exits DePuy Synthes spine portfolio
Johnson & Johnson MedTech will officially exit the DePuy Synthes Spine portfolio in Australia tomorrow, November 30, as part of […]
MoreNews & Trends - Pharmaceuticals
Home-grown hypertension polypill heads to regulatory approval
Australian-supported research has revealed remarkable Phase III clinical trial results for an innovative triple drug combination in the treatment of […]
MoreNews & Trends - Pharmaceuticals
Will Australia become first country to eliminate HIV transmission by 2030?
In the lead-up to World AIDS Day on December 1, the Albanese Government has unveiled the 9th National HIV Strategy, […]
More